Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - adrenaline (epinephrine) acid tartrate, quantity: 18.2 microgram/ml (equivalent: adrenaline (epinephrine), qty 10 microgram/ml); lidocaine hydrochloride, quantity: 10 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide; sodium metabisulfite - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques; infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 20 mg/ml; adrenaline (epinephrine) acid tartrate, quantity: 9.1 microgram/ml (equivalent: adrenaline (epinephrine), qty 5 microgram/ml) - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; sodium metabisulfite; water for injections - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 10 mg/ml; adrenaline (epinephrine) acid tartrate, quantity: 9.1 microgram/ml (equivalent: adrenaline (epinephrine), qty 5 microgram/ml) - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium metabisulfite; sodium hydroxide; sodium chloride - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques; infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 5 mg/ml; adrenaline (epinephrine) acid tartrate, quantity: 9.1 microgram/ml (equivalent: adrenaline (epinephrine), qty 5 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium metabisulfite; hydrochloric acid; sodium hydroxide - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride monohydrate, quantity: 20 mg/ml; adrenaline (epinephrine) acid tartrate, quantity: 22.7 microgram/ml (equivalent: adrenaline (epinephrine), qty microgram/ml) - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adrenaline acid tartrate 0.0091 mg/ml equivalent to 5 µg/ml adrenaline;  ; lidocaine hydrochloride 10 mg/ml; adrenaline acid tartrate 0.0091 mg/ml ([=5mcg/ml adrenaline]); lidocaine hydrochloride 10 mg/ml; adrenaline acid tartrate 0.0091 mg/ml ([=5mcg/ml adrenaline]); lidocaine hydrochloride 10 mg/ml - solution for injection - active: adrenaline acid tartrate 0.0091 mg/ml equivalent to 5 µg/ml adrenaline   lidocaine hydrochloride 10 mg/ml excipient: hydrochloric acid as 2m solution for ph adjustment (ph 3.3-5.0) methyl hydroxybenzoate sodium chloride sodium hydroxide as 2m solution for ph adjustment (ph 3.3-5.0) sodium metabisulfite water for injection active: adrenaline acid tartrate 0.0091 mg/ml ([=5mcg/ml adrenaline]) lidocaine hydrochloride 10 mg/ml excipient: carbon dioxide hydrochloric acid sodium chloride sodium metabisulfite water for injection active: adrenaline acid tartrate 0.0091 mg/ml ([=5mcg/ml adrenaline]) lidocaine hydrochloride 10 mg/ml excipient: carbon dioxide hydrochloric acid sodium chloride sodium hydroxide sodium metabisulfite water for injection - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: · local infiltration · minor or major nerve blocks · epidural block · arthroscopy · intravenous regional anaesthesia

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - adrenaline acid tartrate 0.0091 mg/ml;  ; lidocaine hydrochloride 20 mg/ml; adrenaline acid tartrate 0.0091 mg/ml; lidocaine hydrochloride 20 mg/ml - solution for injection - active: adrenaline acid tartrate 0.0091 mg/ml   lidocaine hydrochloride 20 mg/ml excipient: hydrochloric acid sodium chloride sodium metabisulfite water for injection active: adrenaline acid tartrate 0.0091 mg/ml lidocaine hydrochloride 20 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide sodium metabisulfite water for injection - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques: · local infiltration · minor or major nerve blocks · epidural block · arthroscopy · intravenous regional anaesthesia

Australia - English - Department of Health (Therapeutic Goods Administration)

dentsply sirona pty ltd - adrenaline (epinephrine) acid tartrate, quantity: 22.7 microgram/ml (equivalent: adrenaline (epinephrine), qty 12.5 microgram/ml); lidocaine hydrochloride monohydrate, quantity: 21.3 mg/ml (equivalent: lidocaine hydrochloride, qty 20 mg/ml) - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections; sodium metabisulfite; sodium hydroxide - indications as at 25 july 2003 : lidocaine (lignocaine) solutions are indicated for the production of local anaesthesia in routine dental procedures and oral surgery by means of infiltration and nerve block techniques. lidocaine (lignocaine) solutions with adrenaline (epinephrine) are recommended for oral surgery requiring prolonged duration of anaesthesia and haemostasis.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - lidocaine hydrochloride, quantity: 15 mg/ml; adrenaline (epinephrine) acid tartrate, quantity: 9.1 microgram/ml (equivalent: adrenaline (epinephrine), qty 5 microgram/ml) - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium chloride; sodium hydroxide - xylocaine solutions are indicated for the production of local or regional anaesthesia by the following techniques; infiltration, intravenous regional anaesthesia - excluding solutions with adrenaline, peripheral nerve block such as intercostal block, major plexus block such as brachial plexus block, epidural block, subarachnoid block